Achieve Life Sciences, Inc.
NASDAQACHV enters the week carrying one of the sharpest short-building episodes in the small-cap biotech space, with bears accelerating positions even as the regulatory story becomes more constructive. Short interest has surged to nearly 25% of the free float — a 30% jump in just the past week and a 67% increase over the past month. The move is striking in its speed. From roughly 7.8…
ACHV short interest surges 29.7% in one week to 24.9% of float, highest level in months amid FDA delays for smoking cessation therapy cytisinicline.
Snapshot as of 7 Aug 2026
ACHV enters the week carrying one of the sharpest short-building episodes in the small-cap biotech space, with bears accelerating positions even as the regulatory story becomes more constructive. Short interest has…
Achieve Life Sciences reports Q2 results on July 2 against one of the most charged positioning backdrops in the small-cap biotech universe — a stock up 32% in a month, short sellers at 17.8% of free float, and a borrow…
Three distinct signals are firing on ACHV simultaneously. The borrow market is tightening fast, short interest is elevated and rising, and options traders are piling into calls at a historic rate. The standout signal…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ACHV — free to start on ORTEX.
Sign up for free →Open ACHV on ORTEX